Klinic review
Klinic connects patients with independent medical practices for weight-management assessment. Consultation fees, prescription costs and insurer access are separate decisions.
The verdict
Klinic’s marketplace model can help patients find a provider who accepts their insurance. The clinical relationship is with the independent practice, not the technology platform. That distinction matters for continuity, side-effect support and follow-up fees after the initial appointment.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide · Orforglipron
- Form
- Injection · Oral
- Prescription
- Required
The platform supports several conditions, including obesity, and describes individualized plans that may include Wegovy, Zepbound, oral Wegovy or Foundayo. These are possible treatments, not a guarantee that every clinician or patient can use each option.
Who writes the prescription, and what do they see?
The terms identify Klinic Medical practices and independent prescribing providers as responsible for care. The initial consultation evaluates medical need and eligibility. Confirm the individual clinician’s state authority and whether the selected practice provides the intended weight-management service.
Patients choose a service and book a consultation through the platform. Later care and prescriptions are managed by the provider. Ask whether the same clinician handles reviews, how side effects are communicated and whether messaging between appointments is included.
What happens when the dose goes up?
The prescriber decides dose and suitability. The public homepage does not establish a universal escalation ladder or refill policy across independent practices. Agree on the follow-up schedule before moving ongoing treatment to the service.
What the price includes
The homepage lists self-pay initial visits from $99 and follow-ups from $75, with medication extra. Insurance options can depend on the practice and plan. A low or covered visit does not establish coverage for a particular weight-loss medicine.
What it claims, and what it cites
Named GLP-1 options span semaglutide, tirzepatide and orforglipron products. Route and indication matter, and a provider should explain the exact prescription. The platform’s general medicine menu is not evidence that every product will be available locally or approved by an insurer.
Where it holds up, and where it does not
- Strength: Independent clinical responsibility is disclosed
- Strength: Insurance and self-pay options can be compared
- Strength: Follow-up fees are distinguished from first visits
- Limitation: Care arrangements vary by practice
- Limitation: Medication is outside visit prices
- Limitation: No single platform-wide refill policy
What the evidence says about this kind of treatment
The assessment above is about Klinic. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- Someone looking for an insurance-compatible clinician and willing to verify continuity and ongoing weight-care services.
- Wrong for
- A patient needing one universal medicine-inclusive price or an automatic prescription.
The evidence behind what Klinic prescribes
These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.
- Cochrane Review of Semaglutide for Obesity: 18 Trials Graded
A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
- What Is Orforglipron? A Daily GLP-1 Tablet That Is Not a Peptide
A small-molecule daily tablet, not a peptide. Over 72 weeks in 3,127 adults, weight fell 11.2% on the top dose against 2.1% on placebo. No trial has compared it against an injection.
How Klinic compares
| Seller | Who it suits | Go |
|---|---|---|
| SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | See SkinnyRx → |
| ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | See ShedRx → |
| RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | See RxSpan MD → |
More GLP-1 telehealth sellers reviews: NovaNova MDNoviNovoCare PharmacyNowPatientNP2GO
Sponsored alternative
SkinnyRx
Readers choosing tirzepatide, the one line with a published standing rate
Check SkinnyRx availability →Frequently asked
- Who provides the medical care?
- Independent Klinic Medical practices and prescribing providers, as distinguished in the platform terms.
- Does the visit price include medication?
- No. The homepage explicitly adds medication cost if a prescription is issued.
- Are follow-ups automatically identical across providers?
- The public information does not establish one universal schedule or policy; clarify it with the chosen practice.
Sources for this review
Provider information checked . Terms can change.